CONMED Corporation Highlights New Products and Educational Offerings at the 2013 Annual American Academy of Orthopaedic Surgeons Meeting

UTICA, NEW YORK, Mar 19, 2013 (MARKETWIRE via COMTEX) — CONMED Corporation CNMD +3.06% is proud to announce an exciting line of new products that will be showcased at this year’s American Academy of Orthopaedic Surgeons Annual Meeting in Chicago. The new products that will be available at exhibit booth #2029 include the recently launched Y-Knot(R) all suture anchors and the lithium battery system for Hall(R) battery operated power instruments as well as additional innovations in sports medicine and advanced visualization.

ADVANCED VISUALIZATION

3D-HD Vision System – Our new 3D-HD system provides unparalleled visual acuity and precision for laparoscopic surgery. This new technology may ultimately be advantageous for arthroscopic surgery.

Dry Doc(R) Cannulae – Featuring revolutionary ribbed design, these instruments allow for a stronger hold in skin, muscle and the capsule with clinical benefits of control and patient safety. The Dry Doc is now available in a 7 X 95mm size. This product features double tri-cut seals and a ratcheting stopcock for precise fluid control.

SRS Mini-Open – Building off the success of our Shoulder Restoration System (Cross FT(TM), GENYSYS(TM) Cross FT(TM), Super Revo(R)FT, and ThRevo(R) FT), the new SRS Mini-Open system is a complete line of anchors with needles for surgeons who chose to perform repairs in a mini-open fashion.

OTHER LINVATEC INNOVATIONS

Y-Knot(R) All-Suture Anchors from CONMED Linvatec is a new innovative line of instability suture anchors that preserve native bone and help restore the natural anatomy. Y-Knot anchors feature small size, soft construct, and secure 360 degrees FormFit(TM) fixation. The Y-Knot anchor is made entirely of high strength UHMWPE suture, eliminating the possibility of hard loose-bodies in the joint and its small footprint means more potential for tissue-to-bone contact and enables more points of fixation to be made where they are needed most.

Hall(R) Lithium Battery System – Represents the next generation in battery innovation for powered instruments and delivers a dependable, long-lasting source of power and is the only UL-approved autoclavable lithium battery available today. The Hall(R) Lithium Battery provides nearly twice the power of standard batteries and, based on its compact size and design, is 25% lighter than standard autoclavable batteries for a more balanced instrument. The Hall Charger provides fast charge time in just 30 minutes without the need to discharge first and allows for faster return to service.

MEDICAL EDUCATION

In addition to our product innovations, CONMED offers innovative and informative surgeon educational programs throughout the year. We offer advanced courses in hip, shoulder and knee surgery taught by world renowned surgeons. An example is the upcoming unique program scheduled for April 2013 combining surgical techniques for knee arthroscopy and knee arthroplasty.

Throughout the AAOS meeting, CONMED will host presentations by surgical experts on important current topics in the field of arthroscopic repair.

In addition, CONMED Corporation will be officially launching our “Concept to CONMED” campaign. Celebrating our history of invention and collaboration with the surgical community, we will focus on the Company’s history of leading edge innovation in the field of orthopaedic and arthroscopic surgery, including its history of firsts — from the first in disposable shaver blades, bendable blades and disposable cannulae, to the first in autoclavable 3-chip cameras, to the first in true HD, to the first 3D-HD camera which will be showcased at the meeting.

“This is an exciting time for our Company,” said Joseph Darling, CONMED’s Executive Vice President for Commercial Operations and President of CONMED Linvatec. “Fifty years ago, our founding pioneers, Dr. Terry Tanner who started Concept Inc. and Dr. Robert Hall who started Hall Power, changed the course of surgical medicine. Their work led to incredible advances that at the time made a significant contribution to surgeons and patient outcomes. We felt that the 50-year landmark is a great time to reflect on our past as we look toward the future of bringing additional new innovations to the market that will complement our entire portfolio.”

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company’s total sales.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company’s ability to devise and execute strategies to respond to market conditions.